Reducing the Levels of Akt Activation by PDK1 Knock-in Mutation Protects Neuronal Cultures against Synthetic Amyloid-Beta Peptides by Yang, Shaobin et al.
ORIGINAL RESEARCH
published: 08 January 2018
doi: 10.3389/fnagi.2017.00435
Frontiers in Aging Neuroscience | www.frontiersin.org 1 January 2018 | Volume 9 | Article 435
Edited by:
Catarina Oliveira,
University of Coimbra, Portugal
Reviewed by:
Luke Esposito,
Allen Institute for Brain Science,
United States
Ana I. Duarte,
University of Coimbra, Portugal
*Correspondence:
Jose R. Bayascas
joseramon.bayascas@uab.cat
Received: 29 September 2017
Accepted: 15 December 2017
Published: 08 January 2018
Citation:
Yang S, Pascual-Guiral S, Ponce R,
Giménez-Llort L, Baltrons MA,
Arancio O, Palacio JR, Clos VM,
Yuste VJ and Bayascas JR (2018)
Reducing the Levels of Akt Activation
by PDK1 Knock-in Mutation Protects
Neuronal Cultures against Synthetic
Amyloid-Beta Peptides.
Front. Aging Neurosci. 9:435.
doi: 10.3389/fnagi.2017.00435
Reducing the Levels of Akt Activation
by PDK1 Knock-in Mutation Protects
Neuronal Cultures against Synthetic
Amyloid-Beta Peptides
Shaobin Yang 1, Sònia Pascual-Guiral 1, Rebeca Ponce 1, Lydia Giménez-Llort 2,
María A. Baltrons 3, Ottavio Arancio 4, Jose R. Palacio 5, Victoria M. Clos 6, Victor J. Yuste 1
and Jose R. Bayascas 1*
1Unitat de Bioquímica de Medicina, Departament de Bioquímica i Biologia Molecular, Institut de Neurociències, Universitat
Autònoma de Barcelona, Barcelona, Spain, 2Departament de Psiquiatria i Medicina Legal, Institut de Neurociències,
Universitat Autònoma de Barcelona, Barcelona, Spain, 3Departament de Bioquímica i Biologia Molecular, Institute of
Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, Barcelona, Spain, 4Department of Pathology, The Taub
Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, United States,
5Departament de Biologia Cel.lular, Fisiologia i Immunologia, Institute of Biotechnology and Biomedicine, Universitat
Autònoma de Barcelona, Barcelona, Spain, 6Departament de Farmacologia, Terapèutica i Toxicologia, Institut de
Neurociències, Universitat Autònoma de Barcelona, Barcelona, Spain
The Akt kinase has been widely assumed for years as a key downstream effector of
the PI3K signaling pathway in promoting neuronal survival. This notion was however
challenged by the finding that neuronal survival responses were still preserved in mice
with reduced Akt activity. Moreover, here we show that the Akt signaling is elevated
in the aged brain of two different mice models of Alzheimer Disease. We manipulate
the rate of Akt stimulation by employing knock-in mice expressing a mutant form of
PDK1 (phosphoinositide-dependent protein kinase 1) with reduced, but not abolished,
ability to activate Akt. We found increased membrane localization and activity of the
TACE/ADAM17 α-secretase in the brain of the PDK1 mutant mice with concomitant
TNFR1 processing, which provided neurons with resistance against TNFα-induced
neurotoxicity. Opposite to the Alzheimer Disease transgenic mice, the PDK1 knock-in
mice exhibited an age-dependent attenuation of the unfolding protein response, which
protected the mutant neurons against endoplasmic reticulum stressors. Moreover, these
two mechanisms cooperatively provide the mutant neurons with resistance against
amyloid-beta oligomers, and might singularly also contribute to protect these mice
against amyloid-beta pathology.
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INTRODUCTION
The PI3K (phosphoinositide 3-kinase) signaling pathway regulates cell and organism homeostasis
by controlling fundamental cellular responses that include survival, differentiation, proliferation,
growth, and metabolism (Engelman et al., 2006). Dysregulation of this signaling pathway leads
invariably to pathological manifestations (Vanhaesebroeck et al., 2016). For example, increased
PI3K activation is commonly found in tumor cells (Wong et al., 2010), whereas the inhibition of
Yang et al. PDK1/Akt Axis in Alzheimer Disease
this signaling pathway compromise embryonic development and
promotes diabetes in the adult life (Griffin et al., 2005; Foukas
and Withers, 2010). Also, the activation of PI3K by insulin and
IGF-1 is markedly disturbed in Alzheimer Disease (AD) brain,
leading to sustained activation of Akt (Pei et al., 2003; Rickle et al.,
2004), which in turns causes neurons to become increasingly and
ultimately totally resistant to both agonists (Moloney et al., 2010;
O’Neill et al., 2012; Talbot et al., 2012). This leads to inefficient
GSK3β inhibition and Tau hyperphosphorylation (Ryder et al.,
2004) promoting its self-aggregation (Lippens et al., 2007; Cowan
et al., 2010).
Recently, a number of studies have evidenced that the modest
attenuation of the PI3K signaling pathway might underlie
physiological benefits in terms of cancer, metabolism regulation
and aging (Bartke, 2008). For instance, mice overexpressing
PTEN, the gene coding the phosphatase that antagonizes the
pathway, were shown to be protected from cancer and aging
(Ortega-Molina et al., 2012), whereas the increased lifespan
and decrease age-related pathology associated to some life style
strategies, such as dietary and caloric restriction, might rely on
the limited activation of PI3K by insulin and/or IGF1 (Fontana
et al., 2010). The activation of PI3K by BDNF plays a major role
in the brain: BDNF mRNA and protein levels are decreased in
samples of hippocampal and cortical tissues from AD patients
compared with age-matched control subjects (Phillips et al.,
1991). By contrast, increased serum levels of BDNF were also
reported in both AD and Mild Cognitive Impairment (MCI)
patients (Angelucci et al., 2009). These changes in the levels of
BDNFmay be well related to the different stages of AD pathology.
In fact, many extracellularmolecules including growth factors,
hormones and neurotransmitters signal through their specific
receptors by activating PI3K, which in turn phosphorylates
the membrane phospholipid phosphatydilinositol-(4,5)-
bisphosphate (PtdIns(4,5)P2) at the carbon 3 within the
intracellular inositol ring, to produce the phosphatydilinositol-
(3,4,5)-trisphosphate (PtdIns(3,4,5)P3) second messenger
(Vanhaesebroeck et al., 2001). The signal is terminated by
PTEN, the phosphatase that breaks down the PtdIns(3,4,5)P3
to PtdIns(4,5)P2 (Leslie and Downes, 2004). Increases in the
levels of PtdIns(3,4,5)P3 promote the activation of a number
of effector serine-threonine protein kinases, all belonging to
the AGC family. These include Akt, S6K, SGK, RSK, and PKC
isoforms (Mora et al., 2004). PDK1 is the common master
upstream kinase contributing to the activation of all these group
of PI3K-stimulated AGC family members by phosphorylating
their activation T-loops (Bayascas, 2010).
In the last decade, structural and genetical analysis allowed
the rational design of knock-in mutation strategies to dissect the
regulatory mechanisms of the PI3K/PDK1 downstream signaling
pathway (Bayascas, 2008). Both Akt and PDK1 possess PH
domains that bind to PtdIns(3,4,5)P3 and mediate in this manner
the shuttling and co-localization of the two kinases at the
plasma membrane, allowing PDK1 to activate Akt (Alessi et al.,
1997). PtdIns(3,4,5)P3 promotes also the mTOR complexes-
mediated phosphorylation of the different PI3K-stimulated AGC
family members at a second activating site, the C-terminal
hydrophobic motif, thereby creating a docking site for PDK1
binding, phosphorylation and activation (Biondi et al., 2002).
Mice expressing the mutant form of PDK1 K465E within
the PH-domain incapable of PtdIns(3,4,5)P3 binding showed
a defect in Akt activation (Bayascas et al., 2008), whereas in
mice expressing the mutant form of PDK1 L155E within the
pocket that recognizes the phosphorylated substrate docking
site, PDK1 failed to activate most substrates with the exception
of Akt (Bayascas et al., 2006). The PDK1K465E/K465E mice
were smaller but otherwise fertile and healthy, protected from
diabetes (Bayascas et al., 2008), as well as protected from PTEN-
induced tumorigenesis (Wullschleger et al., 2011). By contrast,
the PDK1L155E/L155E mice were embryonically lethal (Collins
et al., 2003), whilst the restricted expression of the PDK1 L155E
mutant protein to neuronal tissues resulted in microcephaly and
abnormal cortical patterning, leading to cognitive deficits and
disruptive behavior (Cordón-Barris et al., 2016).
Pietri and co-workers showed that the PDK1 kinase, the
central switch in the PI3K signal transduction pathway, was
hyperactivated in the brains of Alzheimer Disease (AD) patients,
and that inhibition of PDK1 restored the cognitive defects and
ameliorated the AD-like pathology in transgenic mice models
of this disease (Pietri et al., 2013). The authors demonstrated
that the inhibition of PDK1 resulted in the translocation of the
Tumor necrosis factor-α (TNF-α)-converting enzyme (TACE) to
the plasma membrane, which promoted TNFR1 and amyloid
precursor protein (APP) shedding, thereby precluding TNFα
toxicity and amyloid-β (Aβ) production. Although encouraging
and promising, complete PDK1 inhibition had deleterious
consequences, since mice started dying following 5 months of
treatment (Pietri et al., 2013). Given the phenotypes of the PDK1
knock-in models, we postulate that inhibition of Akt entails
beneficial consequences in terms of aging and thereby might
have protected mice against amyloid-related pathology, whereas
inhibition of the docking-site dependent PDK1 substrates might
be responsible for the toxicity of the treatment.
To define the contribution of Akt to PDK1 actions along
aging and in AD, a longitudinal study was conducted in
which we genetically manipulated the levels of Akt activity by
employing the PDK1K465E/K465E knock-in mice with reduced
Akt activation but otherwise intact PDK1 signaling. We find
both the TACE protein levels and the TACE α-secretase
catalytic activity increased in the membrane of the PDK1
mutant neurons and brain aged tissues, leading to increased
TNFR1 shedding and reduced sensitivity to TNFα toxicity. We
also provide evidence that, oppositely to the 3xTg-AD mice,
the PERK/eIF2α axis within the unfolding protein response
(UPR) is attenuated in the PDK1K465E/K465E neurons and
brain samples in an age-dependent manner, which confers
cellular resistance against endoplasmic reticulum (ER) stressors
such as tunicamycin. Moreover, the PDK1K465E/K465E neurons
are markedly protected against Aβ-induced neurotoxicity, and
pharmacological inhibition of Akt protected wild type cells
against Aβ-treatment. We propose a synergistic role of Akt
for both the inhibition of TACE-mediated shedding of TNFR1
and the activation of the UPR in mediating Aβ toxicity, which
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highlights the potential of Akt rather than PDK1 inhibitors for
AD treatment.
MATERIALS AND METHODS
Mice
The generation of the PDK1K465E/K465E knock-in mice and
the genotyping procedures were previously described (Bayascas
et al., 2008). The 3xTg-AD mice colony was established by
Dr. Giménez-Llort from progenitors kindly provided by Prof.
Frank M. LaFerla (Oddo et al., 2003), whereas the brain samples
from mice overexpressing APP (K670N:M671L) together with
PS1 (M146L), termed APP/PS1 mice, line 6.2, were provided
by Dr. Arancio at Columbia University (Holcomb et al.,
1998). Transgenic male and female mice and matched non-
transgenic wild type littermates were used in all the experiments.
Mice were housed in pathogen-free facilities, 5–6 per cage,
maintained on a 12-h light/dark cycle (lights on at 07:00) with
ad libitum access to food and water. All animal procedures
were performed in accordance with 2010/63/UE regarding
the care and use of animals for experimental procedures
following the recommendations of the Universitat Autònoma
de Barcelona Ethical Committee for Human and Animal
Experimentation. The protocols were approved by the Ethical
Committee forHuman andAnimal Experimentation, Universitat
Autònoma de Barcelona, and performed under a Generalitat
de Catalunya Project License. The study complies with the
ARRIVE guidelines developed by the NC3Rs (Kilkenny et al.,
2010).
Primary Cultures of Embryonic Neurons
and Cell Assays
Neuronal primary cultures were established from embryonic
day 15,5 (E15,5) embryos as previously described (Zurashvili
et al., 2013). Cortical cells were seeded at a density of 5
× 104 cells/cm2 onto 50µg/ml of poly-D-Lysine-coated 24-
well plates for cell viability studies, or 6-well plates for
western blot analysis, and grown for 6 days in vitro in a
5% CO2 incubator. The hippocampal cells were plated at a
density of 2 × 104 cells/cm2 on 24-well plates containing
12-mm glass coverslips coated with 150µg/ml of poly-D-
Lysine for 4 days in vitro in a 5% CO2 incubator. Stock
solutions of tunicamycin and Akti-1/2 dissolved in dimethyl
sulfoxide, or TNFα and Aβ dissolved in PBS, were added
to cultures as indicated. Cell survival was determined by the
MTT reduction assay as described previously (Zurashvili et al.,
2013). For the quantification of apoptosis, cells were fixed in
2% paraformaldehyde, stained with 1µg/ml of the DNA dye
Hoechst 33342, and then visualized under the fluorescence
microscope. Apoptosis was quantified at each condition point
by scoring the percentage of cells exhibiting fragmented or
condensed nuclei. At least 300 cells per well from 6 systematically
collected fields starting from a random position were manually
counted by two participants, with blinding to the treatment
conditions.
Generation of Protein Extracts and
Western Blot Analysis
Tissue extracts were prepared by homogenizing the frozen
tissue in a 10-fold excess volume of ice-cold lysis buffer
(50 mM Tris-HCl pH 7.5, 1mM EGTA, 1mM EDTA,
1mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM
sodium pyrophosphate, 10mM sodium-glycerophosphate, 0.27
M sucrose, 1% w/v Triton X-100, 0.1% v/v 2-mercaptoethanol,
and a 1:100 dilution of protease inhibitor cocktail, (Sigma, Merck
KGaA, Darmstadt, Germany) using the Polytron homogenizer;
cultured cortical neurons were scrapped from wells in the
same ice-cold lysis buffer. Lysates were centrifuged at 4◦C
for 15min at 15,000 × g and supernatants aliquoted and
preserved at −20◦C. Protein concentrations were determined
by the Bradford method using bovine serum albumin as
standard. The activation state of the different pathways was
assessed by loading 20µg of protein extracts onto 6–10%
polyacrylamide, 0.25M Tris-HCl pH 8.5, 0.1% (w/v) SDS gels
casted in 10-well/1mm-thick mini-PAGE (polyacrylamide gel
electrophoresis) system (Bio-Rad, Hercules, California, USA),
then electrophoresed on 25 mM Tris-HCl pH 8.5, 192 mM
Glycine, 0.1% (w/v) SDS running buffer at 160 V for 60 min,
and finally transferred to nitrocellulose membranes (Whatman,
Maidstone, UK) on a 25 mM Tris-HCl pH 8.5, 192 mM
Glycine, 20% methanol transfer buffer wet system at 100 V
for 90min. Samples were blocked with 10% skimmed milk,
1xTBS, 0.2% (w/v) Tween 20 for 1 h at room temperature,
then immunoblotted over night at 4◦C with 1µg/ml of the
indicated primary antibodies diluted in either 5% skimmed
milk, 1xTBS, 0.2% (w/v) Tween 20 (total protein antibodies) or
0.5% BSA, 1xTBS, 0.2% (w/v) Tween 20 (phospho-antibodies),
which were detected with a 1:5,000 dilution of the appropriate
horseradish peroxidase-conjugated secondary antibodies diluted
in 5% skimmed milk, 1xTBS, 0.2% (w/v) Tween 20. Membranes
were incubated with the enhanced chemiluminescence (ECL)
reagent, then either exposed to Super RX Fujifilm and developed,
or detected using a ChemiDoc MP Imaging System (Bio-Rad,
Hercules, California, USA), and quantified using the ImageJ
software.
Membrane and Cytosol Preparation
Cortex tissues were homogenized in 10 volumes of cold
homogenization buffer (50 mMTris-HCl pH 7.4, 0.27 M sucrose,
1 mM Na3VO4, 1mM EDTA, 1 mM EGTA, 50 mM NaF, 5
mM sodium pyrophosphate, 10 mM sodium-glycerophosphate,
and a 1:100 dilution of protease inhibitor cocktail (Sigma,
Merck KGaA, Darmstadt, Germany) 50 strokes using a glass
potter homogenizer. Homogenates were centrifuged at 1,000× g
for 15 min at 4◦C to remove cellular debris. The cleared
homogenates were centrifuged at 20,000 × g for 1 h at 4◦C
and the resultant supernatant collected as the cytosolic fraction;
the pellet was resuspended and washed in the same volume
of homogenization buffer at 20,000 × g for 1 h at 4◦C.
The supernatant was discarded and the pellet containing the
membrane fraction resuspended in 1% SDS homogenization
buffer.
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Preparation of Amyloid-Beta Oligomers
Aβ oligomers were prepared as shown previously (Manterola
et al., 2013). One mg of synthetic amyloid-β peptides (1-42) from
amino acid 672–713 in the human amyloid precursor protein
sequence (catalog number H-1368.1000, Bachem, Torrance,
USA) was monomerized in hexafluor-2-propanol and then
evaporated peptides resuspended in 20µl of fresh anhydrous
DMSO, vortexed 20 s, incubated 5 min at room temperature, and
diluted with 424µl of PBS to a final concentration of 500µM.
The solution was again vortexed, incubated at 4◦C for 24 h,
and then centrifuged at 14,000 × g 4◦C for 10 min to remove
insoluble pellets. The supernatant containing amixture of soluble
Aβ1−42 oligomers was collected and biochemically analyzed by
Bicine/Tris/Urea SDS-PAGE (Figure 9A). 1.6M Tris-HCl pH
8.1, 8M urea, 0.4M H2SO4 resolving and 0.8M BisTris pH 6.7,
0.2M H2SO4 stacking gels were casted in 10-well/1mm-thick
mini PAGE system (Bio-Rad, Hercules, California, USA), then
electrophoresed on 0.2MBicine pH 8.2, 0.1MNaOH, 0.25% (w/v)
SDS cathode and 0.2M Tris-HCl pH8.1, 0.05M H2SO4 anode
running buffers at 100 V for 100 min, finally transferred to PVDF
membranes (Whatman, Maidstone, UK) on a 10mM CAPS pH
11, 10% methanol transfer buffer wet system at 200 mA for 90
min, and then immunoblotted as described.
Tace Immunoprecipitation and Tace
Activity
1µg of anti-TACE antibody was conjugated with 10µl of
Protein G Sepharose (GE Healthcare, Chicago, Illinois, USA)
and incubated with 0.2mg of pre-cleared tissue lysates overnight
at 4◦C on a shaking platform. The beads were washed
three times with 1 ml of lysis buffer supplemented with
150 mM NaCl, resuspended in protein sample loading buffer,
electrophoresed and then immunoblotted with the indicated
antibodies. TACE activity was determined using the SensoLyte
520 TACE (α-Secretase) Activity Assay Kit (#AS-72085, AnaSpec,
Inc., Fremont, USA) following the manufacturer’s instructions.
Reaction was started by adding 40 mM of the fluorophoric
QXL520/5FAM FRET substrate and was allowed to proceed for
60 min. 30µg of cortex and hippocampus, or 20µg of cell lysate
proteins were used. Fluorescence intensity was quantified in a
fluorescence microplate reader (FLx800, BIO-TEK Instruments,
Winooski, USA) at an excitation of 490 nm and emission of 520
nm. Results are expressed as the percentage of fold-change in
fluorescence intensity compared to control samples.
Quantification of BDNF and sTNFR1
Cortex and hippocampus BDNF levels were measured with
the BDNF Quantikine ELISA Kit (#DBD00, R&D Systems Inc.,
Minneapolis, MN, USA) according to the manufacturer
instructions. The levels of the cleaved soluble TNFR1
fragment were measured on either cortex and hippocampus
protein extracts or cell culture medium by using the mouse
sTNFR1 Quantikine ELISA Kit (#MRT10, R&D Systems, Inc.,
Minneapolis, USA) according to the manufacturer’s instructions.
Optical density of each well was measured using an automated
microplate reader (GloMax-Multi Microplate Reader, Promega,
Madison, Wisconsin, USA).
Mouse Cytokine/Chemokine Assays
Mouse Cytokine/Chemokine Magnetic Bead Panel
(MCYTOMAG-70K-PMX, Millipore, Burlington,
Massachusetts, USA) was employed according to manufacturer’s
instructions to assess the serum concentration of 24 different
cytokines and chemokines. The data was obtained with
the Xponent software and the cytokine/chemokine factor
concentrations calculated based on the corresponding standard
curves. All samples were analyzed in duplicate.
Brain Immunohistochemistry
Three 21-months old PDK1+/+ and PDK1K465E/K465E matched
mice were sacrificed by cervical dislocation and brains were
immediately collected, frozen in isopentane cooled down
to −80◦C and stored at −80◦C. Brains were embedded
in O.C.T. Compound (Sakura Finetek, Tokyo, Japan) and
sliced into 10µm thick sagittal sections. Frozen sections
were fixed in 4% paraformaldehyde for 40 min at 4◦C. For
antigen retrieval, sections were boiled 10 min in 10mM
sodium citrate pH 6, cooled down for 30min on ice and
then washed three times with Tris-buffered saline (TBS;
25mM Tris pH 7.5, 150 mM NaCl). Samples were blocked
with buffer containing 5% goat serum and 0.02% Triton
in TBS for 30 min and incubated overnight at 4◦C with
primary antibodies diluted 1:100 in the same blocking
buffer. Sections were washed three times with TBS buffer,
incubated with the corresponding Alexa488 conjugated
secondary antibodies diluted 1:400 in blocking buffer for 1.5
h at room temperature, and counterstained with 1µg/ml
Hoechst 33342 before mounting in Fluorsave reagent (Southern
Biotec, Birmingham, USA). Immunostained sections were
photographed with a Nikon Eclipse 90i epifluorescence
microscope, the captured images were processed and the
staining intensity was measured automatically along a grid line
by using ImageJ 1.42q (Wayne Rasband, National Institutes
of Health, USA) and Fiji (https://imagej.net/Fiji) softwares in
5 selected cortex or hippocampus sections per mouse using
a sum projection of five Z-sections (1µm/section), whereas
Hoechst staining was used to determine the nuclear area for
normalization.
Immunocytochemistry
Dissociated cortical and hippocampal cells were fixed with 4%
paraformaldehyde in PBS for 20 min at room temperature,
washed three times with PBS for 5 min with slow agitation,
permeabilized with 0.02% saponin in PBS for 7 min at room
temperature, incubated 15 min in 0.01% saponin, 10 mM glycine
in PBS, and then blocked in 0.01% saponin, 5% BSA, 10 mM
glycine in PBS for 1 h. Primary antibodies were diluted 1:100
in PBS supplemented with 0.01% saponin-1% normal goat
serum and incubated overnight at 4◦C. Cells were then washed
four times, corresponding secondary antibodies conjugated to
Alexa488 fluorescent dye were used at a concentration of 1:400,
and nuclei were stained with 1µg/ml Hoechst 33342 for 90
min at room temperature. Cover slips were then mounted
with FluoroSave Reagent on microscope slides to measure the
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intensity of the immunostaining signals as described in the
immunohistochemistry section.
Antibodies
The following antibodies were raised in sheep and affinity
purified on the appropriate antigen. The Akt total antibody
was raised against the sequence RPHFPQFSYSASGTA,
corresponding to residues 466–480 of rat Akt; the total
TSC2 antibody was raised against a sequence encompassing
residues 1719–1814 of mouse TSC2; the total PRAS40 antibody
was raised against the peptide DLPRPRLNTSDFQKLKRKY,
corresponding to residues 238–256 of human PRAS40; total
TrkB (catalog number 4603), total ERK (catalog number 9102),
phospho-Akt Thr308 (catalog number 9275), phospho-Akt
Ser473 (catalog number 9271), phospho-GSK3α/β Ser21/9
(catalog number 9331), phospho-FOXO1 Ser256 (catalog
number 9461), total FOXO1 (catalog number 2880), phospho-
TSC2 Thr1462 (catalog number 3611), phospho-PRAS40
Thr246 (catalog number 2997), phospho-PDK1 Ser241 (catalog
number 3061), total PDK1 (catalog number 3062), phospho-
Threonine (catalog number 9381), phospho-PERK Thr980
(catalog number 3179), total PERK (catalog number 5683),
phospho-eIF2α Ser51 (catalog number 3597), BiP (catalog
number 3177), IRE1α (catalog number 3294), CHOP (catalog
number 2895) and PDI (catalog number 3501) antibodies
were purchased from Cell Signaling Technology, Danvers,
Massachusetts, USA. Total GSK3α/β (catalog number sc-7291)
antibody was purchased from Santa Cruz Biotechnology,
Dallas, Texas, USA. TACE antibody was purchased from QED
Bioscience, San Diego, California, USA (catalog number QEB-
1131). TNFR1 antibody was obtained from MBL International,
Woburn, Massachusetts, USA (catalog number JM-3125).
GAPDH antibody was from Abcam, Cambridge, UK (catalog
number ab8245). Aβ (6E10) monoclonal antibody was obtain
from Biolegend, San Diego, California, USA (catalog number
Sig-39345-200). APP antibody was purchased from Sigma,
Merck KGaA, Darmstadt, Germany (catalog number 8717).
For immunoblot analysis, appropriate secondary antibodies
coupled to horseradish peroxidase were obtained from Thermo,
Waltham, Massachusetts, USA. For immunohistochemistry
and immunocytochemistry analysis, the Alexa Fluor 488-
conjugated goat anti-rabbit secondary antibody was obtained
from Invitrogen, Waltham, Massachusetts, USA (catalog number
A11008).
Statistical Analysis
Data was analyzed using GraphPad software (GraphPad Software
Inc., La Jolla, CA, USA). Statistical significance of the difference
between two groups was determined by using the unpaired, two
tailed Student’s t-test analysis. Multiple groups were assessed
by One-way analysis of variance (ANOVA), and the statistical
significance of the differences between categories analyzed by
Post-hoc using Tukey test. Results are presented as the mean
± standard error of the mean. P-values of <0.05 and <0.005
between categories were considered significant and are indicated
in the figures.
RESULTS
Hyperactivation of the PDK1/Akt Signaling
Axis in AD Transgenic Mice Models
AD is an age-related neurodegenerative disorder disturbing
the function of particular brain regions such as cortex and
hippocampus (Huang and Mucke, 2012). To investigate the
importance of the PDK1/Akt signaling in AD, we took advantage
of the PDK1K465E/K465E mice, in which we showed that BDNF-
mediated activation of Akt was impaired in a time and
dose-dependent manner (Zurashvili et al., 2013). As expected,
mutation of the PDK1 phosphoinositide binding site in the
PDK1K465E/K465E mice caused a reduction in the levels of Akt
activity along the whole adulthood both in the cortex (Figure 1A)
and the hippocampus (Figure 1B). This is denoted by the
decrease in the levels of phosphorylation of the Akt substrates
PRAS40 at the Thr246 and TSC2 at the Thr1462 specific Akt
sites, which originated from the decreased phosphorylation of
Akt at the Thr308 residue within the activation loop by PDK1,
but not the Ser473 within the hydrophobic motif domain that
is phosphorylated by mTORC2. Of note, the deficits in Akt
signaling tend to be attenuated in the aged 16–21 months-old
mice brain, which correlated with elevated levels of BDNF both in
the cortex (Figure 1C) and the hippocampus (Figure 1D) mutant
tissue extracts.
We next monitored the degree of activation of this signaling
pathway in brain tissues derived from 3xTg-AD and APP/PS1
transgenic mice and their corresponding matched control
littermates at different ages of life. Strikingly, the levels of
autophosphorylation of PDK1 at the Ser241 activation loop
site, and those of Akt at both Thr308 and Ser473 activating
residues were 50% higher both in the cortex (Figure 2A)
and the hippocampus (Figure 2B) of the 3xTg-AD transgenic
mice, which was accompanied by similar increase in the
phosphorylation of the Akt substrate PRAS40 at Thr246 and,
to a lesser extent, of GSK3β at Ser9 and FOXO1 at Ser256,
their specific Akt sites. This biochemical alteration was already
detectable in the 3xTg-AD transgenic mice at pre-pathological
stages of the disease (6 months of age) and became accentuated
by 12 months of age when the symptoms are overt (Oddo et al.,
2008). By contrast, the PDK1/Akt signaling was found slightly
attenuated in the cortex of the APP/PS1 mice at 6 months of
age (Supplementary Figure 1A), and up to 2-fold increased by 12
months of age (Supplementary Figure 1B).
Increased Tace Activity and Elevated
Soluble TNFR1 Levels in the Aged
PDK1K465E/K465E Knock-in Mice Cortex and
Hippocampus
Aging is the most prominent non-genetic risk factor for AD and
is characterized by a progressive deterioration in the homeostasis
of the neuro-immuno-endocrine systems. In particular, the
increase in the secretion of inflammatory cytokines may play
a vital role in the occurrence and development of AD (Wang
et al., 2015). We therefore profiled the serum levels of a
number of cytokines in the PDK1K465E/K465E mice compared
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FIGURE 1 | Reduced Akt activity in the PDK1K465E/K465E mice brain. Cortical (A) and hippocampal (B) tissues from PDK1+/+ wild type (WT, black bars) and
PDK1K465E/K465E mutant (K465E, white bars) mice of the depicted age in months were subjected to immunoblot analysis with the indicated phospho- and total
antibodies. Each lane corresponds to a sample derived from a different mouse. Band densitometry quantification of the ratio between phosphorylated and total
protein levels is shown at the bottom of each panel, where values are represented as percentage of 4-months old wild type controls. The concentration of BDNF was
measured in the cortex (C) and hippocampus (D) from the same PDK1+/+ wild type (WT) and PDK1K465E/K465E mutant (K465E) mice at the indicated age in
months. The data are represented as the mean ± SEM for at least three different mice per genotype. *p < 0.05 (Student’s t-test) between mutants and controls.
#p < 0.05 (Tukey test) compared to 4 months of age.
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FIGURE 2 | Hyperactivation of the Akt signaling in the 3xTg-AD mice brain. Cortex (A) and hippocampus (B) protein extracts obtained from wild type (WT) and triple
transgenic AD mice model (3xTg-AD) at 6 and 12 months of age were subjected to immunoblot analysis with the indicated phospho and total antibodies. Each lane
corresponds to a sample derived from a different mouse. Band densitometry quantification of the ratio between phosphorylated and total protein levels represented as
percentage of 6-months old wild type controls is shown below the panels. The data are represented as the mean ± SEM for at least three different mice per genotype.
*p < 0.05 and **p < 0.005 compared to controls as obtained by the Student’s t-test. #p < 0.05 and ##p < 0.005 (Tukey test) compared to 6 months of age.
to PDK1+/+ control littermate mice at different ages of life.
Interestingly, the levels of IL-2, IL-9, and TNFα, three cytokines
commonly elevated in AD, were also 10-, 4- and 2-fold increased
respectively in the PDK1+/+ control aged mice, but not in the
PDK1K465E/K465E mutant mice (Supplementary Figure 2).
We focused our attention on TNFα, an inflammatory cytokine
acting through two specific transmembrane receptors, termed
TNFR1 and 2, which have been reportedly shown to contribute
to AD-related brain inflammation and to modulate neuronal
viability (Yang et al., 2002; Li et al., 2004). TACE mediates
the shedding of TNF-α and the two TNF-α receptors TNFR1
and TNFR2 (Gooz, 2010), as well as the α-secretase-mediated
cleavage of APP (Buxbaum et al., 1998). We first analyzed by
western blot the levels of expression of TACE, TNFR1 and APP in
cortical (Figure 3A) and hippocampal (Figure 3B) total protein
extracts derived from PDK1K465E/K465E mutant and PDK1+/+
control littermate mice at different ages of life, and found
no differences between genotypes along the entire adulthood.
Likewise, unaltered TACE and TNFR1 protein levels were also
observed in the cortex and the hippocampus of 3xTg-AD
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FIGURE 3 | Increased TACE α-secretase activity and soluble TNFR1 levels in the aged PDK1K465E/K465E mice cortex. Cortical (A) and hippocampal (B) tissue
extracts from PDK1+/+ wild type (WT, black bars) and PDK1K465E/K465E mutant (K465E, white bars) mice of the indicated age in months were subjected to
immunoblot analysis with the described antibodies. Each lane corresponds to a sample derived from a different mouse. Band densitometry quantification normalized
to GAPDH levels is shown at the bottom and expressed as a percentage of the 4 months-old wild type controls. The TACE α-secretase activity (C,E) and
concentration of soluble TNFR1 (D,F) were measured on cortical and hippocampal protein extracts from the same PDK1+/+ wild type (WT) and PDK1K465E/K465E
mutant (K465E) mice at the indicated age in months. The data are represented as the mean ± SEM for at least three different mice per genotype. *p < 0.05 compared
with wild types as obtained by the Student’s t-test. #p < 0.05 compared to 4 months of age as obtained by the Tukey test.
(Figure 2) and in the cortex of the APP/PS1 (Supplementary
Figure 1) transgenic mice at either 6 or 12 months of age.
We next determined the TACE α-secretase catalytic activity
levels in cortical and hippocampal protein extracts, which were
around 20% higher in the cortex of the 16- and 21-month
old and at 12- and 16-month in the hippocampus of the aged
PDK1K465E/K465E mice compared to the young mutant mice
samples or the PDK1+/+ control littermate mice (Figures 3C,E).
In agreement with that, the soluble TNFR1 levels were
accordingly increased both in the cortex and the hippocampus
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of the PDK1K465E/K465E knock-in mice compared to the controls
(Figures 3D,F).
Increased Levels of Tace with Decreased
TNFR1 Levels in the Plasma Membrane of
the PDK1K465E/K465E Knock-in Mice
Neurons
The α-secretase activity of TACE is mainly regulated by
controlling its localization to the plasma membrane (Edwards
et al., 2009). Phosphorylation of TACE at the C-terminus
cytosolic domain by different upstream kinases modulate TACE
trafficking (Gooz, 2010). Among them, PDK1 has been proposed
to promote TACE phosphorylation and internalization (Pietri
et al., 2013). Given the increased cortical TACE α-secretase
activity observed in the PDK1K465E/K465E mutant samples in
which the Akt kinase activity is reduced, we sought to determine
the consequences of this signaling lesion for TACE subcellular
localization. TACE protein levels were three times more
abundant in the membrane fractions of the PDK1K465E/K465E 21-
months old mice brain when compared to their corresponding
controls, which was accompanied by a nearly absence of TNFR1
protein in those subcellular fractions (Figure 4A). This was
corroborated by immunohistochemical analysis, which revealed
a 40% increase in TACE surface staining and a 20% decreased
detection of TNFR1 in the 21-months old PDK1K465E/K465E mice
brain cortical and hippocampal sections compared to the controls
(Figure 4C). Of note, the levels of phosphorylation of TACE, as
detected with antibodies raised against phosphorylated threonine
residues, were nearly 2-fold reduced in the PDK1K465E/K465E
TACE immunoprecipitates compared to the controls, thereby
raising the possibility of Akt being a major upstream kinase
downstream of PDK1 governing the phosphorylation and
shuttling of TACE (Figure 4B).
Reduced Vulnerability of the
PDK1K465E/K465E Primary Cortical Neurons
to TNFα–Induced Toxicity
TNFα is synthesized as a membrane-bound pro-protein which
is processed by TACE to generate the mature cytokine. Since
TNFα can elicit pro-apoptotic signals acting through TNFR1,
we next aimed to determine whether the increased TNFR1
shedding observed in the PDK1 mutant mice brain could be
instrumental in protecting primary cultures of cortical neurons
against TNFα toxicity. Immunocytochemical analysis of cortical
neurons exposed to 100 ng/ml TNFα for 24 h revealed a marked
40% decrease in the levels of TACE and a clear 40% increase in
the levels of membrane-bound TNFR1 in the wild type samples,
but not in the mutant cultures (Figure 5A). Accordingly, similar
reduction both in the α-secretase activity of TACE as well as
in the concentration of soluble TNFR1 released to the culture
media was observed in the wild type cells, which was significantly
attenuated in the mutant neurons (Figures 5B,C). In spite of
these data, TNFα failed to compromise cell viability both in
the wild type and the mutant cultures (Figure 5D). Neurons
can overcome the pro-apoptotic signals dictated by TNFα
by expressing the anti-apoptotic Bcl-2 family member Bcl-XL
(Gozzelino et al., 2008). Treatment of the cells with TNFα in the
presence of the broad RNA synthesis inhibitor Actinomycin-D
drastically reduced the cell viability of the wild type cultures, as
denoted by a 70% decrease in the MTT assay values, but to a
lesser extent in themutant cells, which exhibited a significant 50%
decrease instead.
Age-Dependent Attenuation of the
PERK/EIF2A Axis within the Unfolding
Protein Response in the PDK1K465E/K465E
Mice
The accumulation of misfolded proteins is a common
characteristic of neurodegenerative syndromes such as AD,
and alterations in the ability of the endoplasmic reticulum (ER)
to counteract this stress through the unfolding protein response
(UPR) could represent a molecular connection among these
neurodegenerative diseases (Mercado et al., 2013). This adaptive
response consists on a complex signaling network restoring
homeostasis or triggering apoptotic cell dead depending on the
intensity of the insult. We monitored the UPR by western blot
analysis with specific antibodies against different elements on
this signaling cascade. Among them, we consistently found up to
5-fold decreased levels of phosphorylation of the PERK kinase at
Thr980 within the activation segment, which was accompanied
by a 2-fold reduction in the levels of phosphorylation of the
eIF2α substrate at the specific Ser51 PERK site, in the cortex of
the PDK1K465E/K465E aged mice compared to either the wild type
or the young mice (Figure 6A). In sharp contrast, the levels of
phosphorylation of both PERK at Thr980 and eIF2α at Ser51
were increased by 2-fold in the cortex of the 12-months old
3xTg-AD mice (Figure 6B), whereas the protein levels of other
components of the UPR analyzed such as BIP, PDI, IRE1α or
CHOP remained unchanged between genotypes.
Attenuated UPR Signaling in the
PDK1K465E/K465E Primary Cortical Neurons
Confers Resistance to ER Stress
The hyperactivation of the PERK/eIF2α signaling observed in
the 3xTg-AD mice cortex is most likely caused by the exposure
of the neurons to elevated levels of Aβ peptides, which could
contribute to the neuronal loss observed in this model of disease.
In order to clarify whether the attenuated levels of PERK/eIF2α
phosphorylation observed in the aged PDK1K465E/K465E mice
cortex could have physiological consequences, primary cultures
of cortical neurons derived from PDK1K465E/K465E and PDK1+/+
mice were treated with tunicamycin, a compound blocking
the initial step of glycoprotein biosynthesis that causes the
accumulation of unfolded glycoproteins, therefore leading to
ER stress. Tunicamycin treatment caused a dramatic up to
90% dose-dependent reduction of cell viability, as assayed with
the MTT method, which was followed by a vast up to 5-fold
increase in the percentage of cells exhibiting apoptotic nuclear
morphology in the control cells. Interestingly, cell viability
was two times higher, and the percentage of apoptotic cells
20% reduced, in the PDK1K465E/K465E neurons compared to
the controls (Figure 7A). These differences can be attributed
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FIGURE 4 | Increased TACE and decreased TNFR1 protein levels at the plasma membrane in the PDK1K465E/K465E knock-in mice brain. (A) Brain cytosolic (CYT)
and membrane (MEM) subcellular fractions obtained from PDK1+/+ wild type (WT, black bars) and PDK1K465E/K465E mutant (K465E, white bars) 21-months old
mice were immunoblotted with the indicated antibodies, where ERK1/2 and TrkB are employed as cytosolic and membrane markers, respectively. (B) TACE was
immunoprecipitated (IP TACE) with specific antibodies from total brain protein extracts from PDK1+/+ wild type (WT) and PDK1K465E/K465E mutant (K465E)
21-months old mice and immunoblotted both with TACE and pan-pThr antibodies, as depicted. The levels of TACE in the total cellular lysates and the immunoglobulin
controls (IgG) are also shown. (A,B) Representative Western blots of three independent experiments are shown, and the band densitometry quantification expressed
as a percentage of the wild type controls is plotted at the bottom. (C) Representative epifluorescence micrographs of cortical and CA3 middle hippocampal sections
obtained from PDK1+/+ wild type (WT) and PDK1K465E/K465E mutant (K465E) 21-months old mice brain stained with TACE, TNFR1, and the nuclear Hoechst dye;
arrows indicate the specific surface staining; the intensity of the signals were quantified and expressed as a percentage of the wild type controls. The data are
represented as the mean ± SEM for at least three different mice per genotype. *p < 0.05 and **p < 0.005 compared with wild types as obtained by the Student’s
t-test.
to the attenuated tunicamycin-induction of the UPR observed
in the PDK1K465E/K465E mutant samples, as denoted by the
decreased levels of phospho-PERK Thr890 and phospho-
eIF2α Ser-51, but not the BIP, PDI or IRE1α protein levels
(Figure 7B).
Reduced Activation of Akt Protected the
PDK1K465E/K465E Neurons against
Aβ–Induced Cell Death
The accumulation of plaques containing misfolded Aβ peptides
is a characteristic neuroanatomical hallmark of AD and at the
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FIGURE 5 | Reduced TNFα–induced cell death in the PDK1K465E/K465E neurons. Primary cultures of cortical neurons obtained from PDK1+/+ wild type (WT, black
bars) and PDK1K465E/K465E mutant (K465E, white bars) E15,5 embryos were grown for 6 days in vitro and then treated or not with 100 ng/ml of recombinant TNFα
and/or1 nM Actinomycin D for 24 h, as indicated. (A) Representative epifluorescence images stained with TACE or TNFR1 and merged with the nuclear Hoechst dye,
as indicated; bars, 50 and 30µm for TACE and TNFR1, respectively; quantification of the cell surface signals is shown below as the mean ± SEM for 200 neurons
from four different embryos per condition, and expressed as a percentage of the wild type controls. The TACE α-secretase activity (B) and the levels of soluble TNFR1
in the culture medium (C) were also determined and expressed as the mean ± SEM from four different embryos per condition. (D) Cell viability was determined by the
MTT reduction assay and represented as the mean ± SEM for at least five independent embryos per genotype from two separate experiments, with each sample
assayed in triplicate. *p < 0.05 and **p < 0.005 compared with wild types as obtained by the Student’s t-test. #p < 0.05 and ##p < 0.005 between controls and
treatments analyzed by the Tukey test.
same time a central contributing factor to neurotoxicity. Since
the reduced activation of Akt in the PDK1K465E/K465E neurons
protected cells against TNFα and ER stress, two proposed key
mediators of Aβ-induced pathology, and the PDK1/Akt signaling
pathway is hyperactivated in AD transgenic mice models, we
reasoned that the PDK1K465E/K465E mutant neurons should be
also protected from Aβ-induced neurotoxicity. As expected, the
exposure of primary cultures of wild type cortical neurons to
Aβ oligomers elicited a dramatic dose-dependent reduction of
up to 50% in cell viability, which is accompanied by a massive
increase in the percentage of apoptotic cells reaching 50% values
at the highest doses of Aβ tested. Remarkably, both the loss
of cell viability as well as the increase in the percentage of
apoptotic cells are clearly attenuated in the PDK1K465E/K465E
neurons, in which a 20% decrease in cell viability and a 30%
of apoptotic cells are observed at the highest concentration
of Aβ oligomers (Figure 8A). Of note, Aβ treatment did not
change the levels of activation of Akt, as judged by the levels
of phosphorylation of Akt at the Thr308, PDK1 activation site,
as well as the levels of phosphorylation of the Akt substrates
PRAS40 at Thr246 and TSC2 at Thr1462, which were as expected
consistently reduced in the PDK1K465E/K465E protein extracts
compared to the controls along the whole treatment (Figure 8B).
By contrast, the exposure of the neurons to Aβ oligomers induced
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FIGURE 6 | Opposite changes of the PERK/eIF2α axis within the UPR in the PDK1K465E/K465E mice and the 3xTg-AD mice. Cortical brain extracts from PDK1+/+
wild type (WT, black bars) and PDK1K465E/K465E mutant (K465E, white bars) mice of the different ages (A), or 12-months old wild type (WT) and triple transgenic AD
mice (3xTg-AD) model (B), were subjected to immunoblot analysis with the indicated antibodies. Each lane corresponds to a sample derived from a different mouse.
Band densitometry quantification of the ratio between the indicated markers and control levels is shown at the bottom (A) or at the right (B) expressed as a
percentage of the 4-months old wild type controls. *p < 0.05 or **p < 0.005 compared with wild types as obtained by the Student’s t-test. #p < 0.05 and
##p < 0.005 compared to 4 months of age as obtained by the Tukey test.
the phosphorylation of PERK at Thr980 and of eIF2α at Ser51
more potently in the PDK1+/+ control neurons than in the
PDK1K465E/K465E mutant ones; BIP protein was only induced
upon 24 h of treatment and to the same level in the two genotypes
analyzed, whereas PDI and IRE1α levels remained unchanged
(Figure 8C). Of note, Aβ treatment also induced a 20% decrease
in the levels of TACE accompanied by a 2.5-fold increase in
the levels of membrane-bound TNFR1 in the control cells,
which were less pronounced in the PDK1K465E/K465E mutant cells
(Figures 8D,E). In agreement with that, the TACE α-secretase
catalytic activity (Figure 8F) as well as the levels of soluble
TNFR1 released to the medium (Figure 8G) were further 10%
reduced in the PDK1+/+ wild type cells when compared to the
PDK1K465E/K465E mutant cultures.
In order to assess the contribution of the Akt signaling to
the Aβ-toxicity protection exhibited by the PDK1K465E/K465E
mutant cells, we pre-treated wild type cultures with increasing
doses of the Akt1 and Akt2 isoform-specific allosteric inhibitor
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FIGURE 7 | Attenuated UPR signaling protects PDK1K465E/K465E neurons against tunicamycin-induced ER stress. Primary cultures of cortical neurons obtained from
PDK1+/+ wild type (WT, black bars) and PDK1K465E/K465E mutant (K465E, white bars) E15,5 embryos were grown for 6 days in vitro and then treated with the
indicated doses of tunicamycin (TM) for 24 h (A), or with 3µg/ml of tunicamycin for the indicated time points (B). (A) left panel, representative micrographs of
Hoechst-stained cortical cultures, where arrowheads indicate apoptotic nuclei, scale bar 10µm; right upper panel, the cell viability was determined with the MTT
reduction assay and is expressed as a percentage of the untreated cells; right bottom panel, the percentage of apoptotic cells was obtained by scoring the number of
nuclei exhibiting chromatin fragmentation divided by the total. Data represents the mean ± SEM for at least five independent embryos per genotype from two
separate experiments, with each sample assayed in triplicate. **p < 0.005 compared with the corresponding wild types for each condition as obtained by the
Student’s t-test. ##p < 0.005 (Tukey test) statistically significant differences between controls and treatments. (B) Protein extracts were obtained from the indicated
cortical cells and then immunoblotted with the depicted antibodies, where total Akt was employed as a loading control.
Akti-1/2 prior to the exposure to Aβ oligomers. Pharmacological
inhibition of Akt activity to levels equivalent to those found in the
PDK1K465E/K465E mutant cells protected wild type cortical cells
against Aβ-induced toxicity, therebymimicking the impact of the
PDK1 K465E mutation in impeding Akt activation (Figure 9).
DISCUSSION
In the present study, we employed the PDK1K465E/K465E knock-
mice with reduced Akt activity but otherwise intact PI3K/PDK1
signaling to interrogate the relevance of this pathway to AD.
These mice were first generated to explore the importance of
the PDK1-PtdIns(3,4,5)P3 interaction regarding Akt activation,
and were meant to be a unique genetic tool to specifically
ablate Akt functions (Bayascas, 2008). Mutation of the PDK1
PH-domain caused a significant reduction in the rate of Akt
activation, which was surprisingly still able to be partially
phosphorylated and activated by PDK1 through the docking
site-dependent mechanism (Najafov et al., 2012; Zhou et al.,
2014). We know report that these deficits in Akt signaling
tend to be attenuated in an age-dependent manner both in the
cortex and the hippocampus, which correlated with elevated
concentration of BDNF in both brain areas in the PDK1 mutant
mice.
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FIGURE 8 | Protection of the PDK1K465E/K465E neurons against Aβ–toxicity. Primary cultures of cortical neurons obtained from PDK1+/+ wild type (WT, black bars)
and PDK1K465E/K465E mutant (K465E, white bars) E15,5 embryos were grown for 6 days in vitro and then treated the indicated concentration of amyloid-β peptides
(Aβ) for 48 h (A), with 5µM of Aβ for the indicated time points in hours (B,C), or with 5µM of Aβ for 24 h (D–G). (A) Upper panel, the cell viability was determined on
the indicated cortical cultures with the MTT reduction assay and is expressed as a percentage of the untreated cells; bottom panel, the percentage of apoptotic cells
was obtained by scoring the number of nuclei exhibiting chromatin fragmentation divided by the total. Data represents the mean ± SEM for at least five independent
embryos per genotype from two separate experiments, with each sample assayed in triplicate. (B,C) Protein extracts from matched PDK1 wild-type (WT) and PDK1
(Continued)
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FIGURE 8 | mutant knock-in (KI) mice were obtained from the indicated cortical cell samples and then immunoblotted with the depicted antibodies.
(D) Representative immunofluorescent labeling of TACE or TNFR1 counterstained with the Hoechst nuclear dye, as indicated; bars, 40 and 30µm for TACE and
TNFR1, respectively. (E) Quantification of the cell surface signals is expressed as the mean ± SEM for 200 neurons from four different embryos per condition, and
expressed as a percentage of the wild type controls. The TACE α-secretase activity (F) and the levels of soluble TNFR1 in the culture medium (G) were also
determined and expressed as the mean ± SEM from four different embryos per condition. *p < 0.05 or **p < 0.005 compared with the corresponding wild types for
each condition as obtained by the Student’s t-test. #p < 0.05 and ##p < 0.005 (Tukey test) statistically significant differences between controls an treatments.
The resultant Akt hypomorphic mice exhibited growth defects
and were smaller but otherwise viable, fertile and healthy through
the adulthood. Moreover, in spite of the essentiality of Akt in the
control of neuronal viability during development (Datta et al.,
1999), the neuronal survival responses were still preserved in
the PDK1K465E/K465E knock-in mice, which exhibited a normal
pattern of cortical layering and connectivity and no signs of brain
age-related pathology (Zurashvili et al., 2013).
What is more, PDK1 activity was found increased in the brain
samples of individuals with AD, whereas inhibition of PDK1
reduced AD pathology in mice but at the same time resulted in
long term toxicity (Pietri et al., 2013). Since the PDK1 L155E
mutation abrogating PDK1 signaling with intact Akt activation
caused profound alterations in mice (Cordón-Barris et al., 2016),
we postulated that inhibition of Akt might have protected mice
against AD, whereas inhibition of the docking-site dependent
PDK1 substrates might have been responsible for the toxicity of
the treatment.
In agreement with that notion, we consistently observed in
the cortex and the hippocampus of two different AD transgenic
mice models an age-dependent increase in the levels of PDK1
activity, as judged by the elevated levels of auto-phosphorylation
at the Ser241 within the PDK1 activation loop as well as the
elevated phosphorylation of the downstream Akt substrates.
Hyperactive PI3K/Akt signaling has been widely documented
in AD mice models (Stein and Johnson, 2002; Sah et al., 2017)
and patients (Tramutola et al., 2015). However, in advances
stages of the disease, sustained Aβ-mediated activation of Akt
caused desensitization of the PI3K pathway to extracellular
signals (Moloney et al., 2010; O’Neill et al., 2012; Talbot
et al., 2012). Indeed, aberrant activation of components of the
insulin signaling pathway, as well as decreased responsiveness
to insulin, are commonly found in post-mortem brain samples
from patients with AD, which were classified as cerebral insulin
resistance (De Felice et al., 2014; Yarchoan and Arnold, 2014;
Biessels and Reagan, 2015). Phosphorylation of the Insulin
Receptor Substrate-1 (IRS1) by the Akt/mTORC1/S6K negative
feedback axis plays a primary role in uncoupling PI3K to a
number of tyrosine kinase receptors (Shah et al., 2004; O’Neill,
2013). Increased phosphorylation of Akt at Ser473 was also
observed in the aged AD transgenic mice mutant samples which
paralleled that of Akt Thr308, the PDK1 site. In contrast, the
deficient activation of Akt observed in the PDK1K465E/K465E mice
arise from inefficient PDK1-mediated phosphorylation of Akt
at Thr308 with intact Akt phosphorylation at Ser473, mTORC2
site. Therefore, a role for mTORC2 hyperactivity in mediating
Aβ-mediated pathology can be envisaged. In this regard, Aβ
was previously shown to induce mTORC1 hyperactivity through
Akt-mediated phosphorylation of PRAS40 in 3xTg-AD mice
(Caccamo et al., 2011). Indeed, we show increased PRAS40
Thr246 phosphorylation both in APP/PS1 and 3xTg-AD old
mice.
The PI3K/Akt signaling pathway is also antagonized by JNK-
mediated phosphorylation of IRS1 in response to inflammatory
factors such as TNFα (Tanti and Jager, 2009). In AD, microglia
activation and pro-inflammatory cytokines production leads to
tau hyperphosphorylation and Aβ accumulation, which in turn
increases the release of these cytokines (Wang et al., 2015). We
found the production of three pro-inflammatory cytokines, IL-2,
IL-9 and TNFα, attenuated in the aged PDK1K465E/K465E mutant
mice. Higher serum TNFα concentrations have been reported
in AD and dementia (Alvarez et al., 1996; Bruunsgaard et al.,
1999). Opposite to the PDK1K465E/K465E aged mice, IL-9 levels
are significantly augmented in AD patients (Dardalhon et al.,
2008), whereas the implication of IL-2 in AD has not been
documented.
The TACE secretase, which is primarily known for its role
in promoting the shedding of cell surface–bound TNFα and
its receptors (Gooz, 2010), mediates also the α-cleavage of the
amyloid precursor protein thereby precluding Aβ production
(Buxbaum et al., 1998). In AD patients, the concentration of the
soluble forms of APPα and TNFR1 in the cerebrospinal fluid
are decreased due to reduced brain TACE α-secretase activity
(Sennvik et al., 2000; Yao et al., 2015). Moreover, inhibition
of PDK1 restored TACE α-secretase activity and cleavage of
APP and TNFR1 in neurons affected by Aβ deposition by
preventing the phosphorylation and internalization of TACE
(Pietri et al., 2013). In accordance with these observations,
we found that while the TACE α-secretase activity and the
levels of sTNFR1 were decreased with aging in brain extracts
from the PDK1+/+ control mice, they were significantly higher
at 16 and 21 months of age in the PDK1K465E/K465E mice
brain when compared to age-matched controls. This was
accompanied by increased TACE with decreased unshedded
TNFR1 accumulation at the plasma membrane of the aged
PDK1K465E/K465E mice brain, which correlated with reduced
phosphorylation of TACE at Thr sites in the mutant samples.
Using TNFR1 shedding as a readout of TACE activity, we
found that the membrane-associated TACE α-secretase activity
and the concentration of sTNFR1 were significantly higher,
whilst the levels of TNFR1 at the cell surface lower, in the
PDK1K465E/K465E neuronal cells treated with Aβ or TNFα
comparedwith the PDK1+/+ wild type cells, thereby pointing out
to a prominent role of Akt downstream of PDK1 in mediating
TACE downregulation induced by Aβ and other inflammatory
factors.
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FIGURE 9 | Reducing the levels of Akt activation protected wild type cortical
neurons against amyloid-beta induced-toxicity. (A) Western blot analysis of the
oligomeric stage of the synthetic Aβ peptides preparation (Syn Aβ42), upon
addition to the primary neurons (Aβ oligomer), and in the discarded insoluble
pellet (fibrillar Aβ). Arrows indicate positions of monomers (1-mer), trimers
(3-mer), tetramers (4-mer) and other higher molecular weight forms (n-mer).
(B) Wild type primary cortical cells were cultured in complete medium for 6
days and then treated in the absence or presence of 5µM of oligomeric
amyloid-β (oAβ) and the indicated concentrations of the Akti-1/2 inhibitor.
Upper panel, the cell viability was determined with the MTT reduction assay
and is expressed as a percentage of the untreated cells; Middle panel, Protein
extracts were obtained from the indicated PDK1 wild-type (WT) and PDK1
mutant knock-in (KI) mice cortical cell samples and then immunoblotted with
indicated phospho and total antibodies; band densitometry quantification of
the ratio between Akt308 phosphorylation and total protein levels is shown at
the bottom, where values are represented as percentage of control. Data
represents the mean ± SEM for at least five independent embryos per
genotype from two separate experiments, with each sample assayed in
triplicate. *p < 0.05 and **p < 0.005 (Student’s t-test) compared with the
untreated controls; #p < 0.05 and ##p < 0.005 (Tukey test) between oAβ
plus the inhibitor and oAβ alone; $p < 0.05 and $$p < 0.005 (Tukey test)
between oAβ plus the different concentration inhibitor and the untreated PDK1
mutant samples.
Decreased TNFR1 levels at the cell surface should render
the PDK1 mutant cells less vulnerable to soluble TNFα-toxicity.
Nevertheless, TNFα only compromised cell viability in the
PDK1+/+ wild type cultures in the presence of the RNA
synthesis inhibitor Actinomycin-D, and to a lesser extent in the
PDK1K465E/K465E mutant cultures. Some studies indicate that
TNFα is a prosurvival factor for neurons (Cheng et al., 1994;
Courtney et al., 1997), that NF-kappaB is not activated by TNFα
in neurons (Jarosinski et al., 2001; Mao et al., 2006; Listwak et al.,
2013), and that the TNFR2 may as well be responsible for TNFα-
induced toxicity (Gary et al., 1998). TNFR1 signaling cascade
is required for Aβ-induced neuronal cell death (Li et al., 2004);
conversely, TNFR1 is required for Aβ generation (He et al., 2007).
In contrast to TNFα, the neurotoxicity elicited by Aβ peptides
was found dramatically attenuated in the PDK1K465E/K465E
neurons compared to the PDK1+/+ controls. That prompted us
to browse for more downstream cellular mechanisms that could
explain the differential sensitivity of the PDK1K465E/K465E mutant
cells to Aβ-related toxicity.
Among them, the UPR is a protective cellular response
induced during periods ER stress, which reduces the unfolded
protein load and returns the protein-folding homeostasis
(Halliday and Mallucci, 2015). In AD, the aberrant proteostasis
of Aβ and Tau induces the UPR and contributes to exacerbate
the neuronal cell loss (Hetz and Mollereau, 2014). For example,
phosphorylation of eIF2α is elevated in the brain of AD patients
and AD mice models, and inhibition of the upstream kinase
PERK prevent deficits in protein synthesis, synaptic plasticity and
spatial memory in APP/PS1 mice (Ma et al., 2013). In agreement
with that notion, we found the levels of phosphorylation of both
PERK at Thr980 and eIF2α at Ser51 markedly increased in the
cortex of the 12-months old 3xTg-AD mice, whereas the protein
levels of other components of the UPR analyzed such as BIP,
PDI, IRE1α or CHOP remained unchanged. In sharp contrast,
phosphorylation of PERK at Thr980 and eIF2α at Ser51 were
reduced in the old PDK1K465E/K465E mutant mice or in mutant
cortical cultures treated with tunicamycin or Aβ compared
with the PDK1+/+ wild type mice and cells. Attenuated Akt
signaling allows the FOXO-mediated transcription of genes
counteracting age-related proteotoxicity in AD mice (Cohen
et al., 2009; Douglas and Dillin, 2010). Moreover, we found
diminished number of apoptotic cells induced by tunicamycin,
which were more robustly attenuated upon Aβ treatment in the
PDK1K465E/K465E neurons compared with the PDK1+/+ wild
type controls, especially when they were used at highest doses.
Therefore, the inefficient binding of PDK1 to PtdIns(3,4,5)P3 in
the PDK1K465E/K465E mice leading to reduced phosphorylation of
Akt at Thr308 and hypoactivation of the downstream signaling
pathway seems to play an important role in attenuating the
UPR in an age-dependent manner. These observations point to
an Akt-dependent activation of the PERK/eIF2α pathway with
aging, which was however previously shown to phosphorylate
and inhibit PERK in cells exposed to ER stress or oxidative
stress (Mounir et al., 2011). All the above findings raise the
possibility of the existence of a positive feedback effect of Akt
on the PERK-eIF2α axis activation under an unbalance of the
ER stress, which might be attenuated in the PDK1K465E/K465E
mice, leading to a reduction in the neuronal cell death response.
In this regard, the ER stress is proposed to contribute to the
development of brain insulin resistance (Fu et al., 2012). PKR,
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the dsRNA-dependent protein kinase, functional homolog of
PERK, has been also shown to mediate brain IRS1 inhibition
and elF2α phosphorylation induced by Aβ and TNFα in mice
and monkeys (Lourenco et al., 2013). Moreover, suppression
of elF2α phosphorylation provides neuroprotection in mouse
models of AD (Ma et al., 2013). This mechanism, together
with the upregulation of TACE and shedding of APP and
TNFR1, could synergistically account for the Aβ-resistance of
the PDK1K465E/K465E neurons, which could be mimicked upon
treatment with the Akti-1/2 compound inhibiting Akt1 and Akt2,
but not Akt3, the isoform whose levels are highly and specifically
enriched in brain tissues. Of note, the compound employed have
nowadays been developed into an orally available drug approved
for human clinical trial in patients with advanced solid tumors
(Yap et al., 2011) and there are currently 217 clinical trials listed
on the NIH clinical trials website (ClinicalTrials.gov) to evaluate
the therapeutic efficacy of Akt inhibitors for the treatment
of cancer. Our results provide genetic construct validity for
Akt inhibition as a promising therapy in the treatment of
AD.
CONCLUSION
We observed age-dependent hyperactivation of the PDK1/Akt
signaling pathway in both the double APP/PS1 and triple
3xTg-AD transgenic mice models of AD, and employed
the PDK1K465E/K465E mice with reduced Akt activity to
interrogate the relevance of this observation. We demonstrated
how the levels of Akt signaling dictate diverse outcomes
regarding TACE activation, TNFR1 processing and UPR
actions, which determine the sensitivity of the neurons
to TNFα, ER stress and ultimately Aβ toxicity. These
findings suggest that the PDK1K465E/K465E mice might be
protected against AD, and provide genetic validation of
Akt as a new therapeutical target for the treatment of this
disease.
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